Algenpantucel-L: Phase III ongoing

NewLink said an independent DSMC found that the open-label, U.S. Phase III IMPRESS trial evaluating gemcitabine or gemcitabine plus 5-fluorouracil (5-FU) with or without HyperAcute Pancreas did not me...